• D-N-Acetylgalactosamine Protocol & QC Guide

  2026-09-30

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for glycoprotein characterization and brain heteropolysaccharides analysis. It is appropriate for aqueous or validated DMSO workflows, but not for ethanol-dependent methods or long-term storage of prepared solutions.

• MTSEA-biotin C5669 for Assay Reliability

  2026-09-29

  Learn how to position MTSEA-biotin (SKU C5669) within cell viability, proliferation, and cytotoxicity workflows without confusing thiol labeling with a direct metabolic readout. This scenario-based guide emphasizes controls, compatibility testing, protocol optimization, and evidence-limited vendor selection.

• ABE9-SpRY for Bystander-Free Mouse Models

  2026-09-29

  The reference study combines the ABE9 adenine base-editing architecture with the PAM-flexible SpRY Cas9 nickase to improve precision in mouse disease-model generation. ABE9-SpRY produced the intended A-to-G substitutions at three of four tested targets, reached efficiencies of up to 96% in individual adult founders, and showed improved product purity and fewer detected off-target events than ABE8e-SpRY at the tested loci.

• Light-Inducible RNA Switches for Gene Therapy Control

  2026-09-28

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translational level, remaining inhibitory in darkness and permitting expression under blue or ambient light. In mouse models, LIRP-regulated AAV2 systems supported light-dependent metabolic intervention and reversible control of retinal VEGF inhibition, providing a proof of concept for more precisely timed gene therapies.

• Balsalazide Disodium for Colitis Imaging Research

  2026-09-28

  Balsalazide disodium is best known as a colon-activated 5-aminosalicylic acid prodrug, but radiolabeling research suggests a second use: studying how tracer signal localizes in ulcerated colon. This article examines the study’s assay-design implications, limitations, and practical controls for inflammation research.

• DiscoveryProbe™ Immunology/Inflammation Compound Library

  2026-09-27

  The DiscoveryProbe™ Immunology/Inflammation Compound Library provides a defined set of 295 bioactive small molecules for screening immune and inflammatory responses and prioritizing follow-up experiments. It is for research assays and target-validation workflows, not for diagnosis, treatment, or direct confirmation of a compound’s mechanism in a particular model.

• Citron OGD2 Links Iron, ROS, and Canker Resistance

  2026-09-26

  The study identifies Citron CmOGD2 as a contributor to resistance against citrus canker, linking iron uptake and reactive oxygen species to a likely ferroptosis-like defense response. It also reveals feedback regulation by CmENO2 and CmZAT10.1, and shows how the Xanthomonas effector pthA4 may disrupt that feedback to favor infection.

• Z-DEVD-FMK: Mapping Caspase Signaling in Tumors

  2026-09-25

  Z-DEVD-FMK is a cell-permeable caspase-3 inhibitor that can help dissect apoptotic signaling—but its broader target profile matters. This article connects inhibitor design to DR5-driven PD-L1 stabilization and shows how to interpret experiments without mistaking pathway perturbation for target specificity.

• CHIR-99021 in Intestinal Organoid Workflows

  2026-09-25

  Use CHIR-99021 as a timed, testable GSK-3 switch—not as a substitute for a defined intestinal differentiation protocol. Pair pathway readouts with controlled culture environments to separate signaling effects from matrix-driven changes in human intestinal organoids.

• Merbromin Inhibits SARS-CoV-2 3CLpro by Mixed-Type Binding

  2026-09-24

  A biochemical screen of approximately 6,000 compounds identified merbromin as an inhibitor of SARS-CoV-2 3CLpro, with enzyme kinetics indicating mixed-type inhibition. Selectivity tests, binding assays, and molecular docking support merbromin as a useful lead for further study, while leaving its antiviral efficacy and therapeutic potential unresolved.

• EdU Flow Cytometry Assay Kits (Cy5) in Wound Biology

  2026-09-24

  Pair S-phase DNA-synthesis measurement with mechanistic studies of epithelial repair to distinguish cell-cycle effects from changes in migration or survival. The Cy5 click-chemistry workflow avoids harsh DNA denaturation and can be integrated with cell-cycle dyes or selected antibody panels.

• Concanamycin A: Read Trafficking Before Cell Death

  2026-09-23

  Concanamycin A is a potent V-type H+-ATPase inhibitor, but its effects reach beyond a single cell-death pathway. This article shows how to use trafficking and acidification readouts to interpret cancer-cell responses without mistaking a downstream phenotype for target engagement.

• Novobiocin Sodium: Applied Research Workflows

  2026-09-23

  Novobiocin Sodium connects bacterial DNA gyrase inhibition with practical workflows for replication stress, cell viability, and exploratory antiparasitic assays. This guide emphasizes fresh-solution handling, quantitative controls, cross-domain interpretation, and troubleshooting for DNA damage, apoptosis, and antibiotic resistance research.

• LAMP1 Controls CXCL10-CXCR3 Macrophage Polarization

  2026-09-22

  A 2024 International Immunopharmacology study identifies LAMP1-linked autophagy as a context-dependent regulator of CXCL10-CXCR3 signaling in macrophages. Its findings show that CXCR3 antagonism can produce opposite polarization outcomes in non-inflammatory and poly(I:C)-stimulated cells, while also reducing experimental acute lung injury.

• Streptavidin-Cy3 for Spatial Mechanism Assays

  2026-09-22

  Streptavidin-Cy3 can connect biotinylated antibodies and nucleic acid probes to spatially resolved evidence. This guide translates the seRNA-NPCm/NPM1/c-Myc/NDRG1 findings into practical assay-selection, control, and interpretation strategies.

7819 records 1/522 page Next 12345 下5页 Last page